Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Novartis: Operating margins disappoints - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Novartis: Operating margins disappoints

Jul 27, 2001

Novartis India has posted a net profit of Rs 92 m for 1QFY02 as against Rs 186 m in the corresponding quarter last year. However, the figures for the year are not comparable as the company demerged its agrochemical business, which resulted in this sharp decline in turnover and profits. The company also decided to exit the lens and lens care business of CibaVision with effect from December 2000 due to unviability of the same.

(Rs m) 1QFY01 1QFY02 FY01
Sales 2,106 1,024 4,033
Other Income 66 46 308
Expenditure 1,824 922 3,479
Operating Profit (EBDIT) 282 102 554
Operating Profit Margin (%) 13.4% 10.0% 13.7%
Interest 4 2 7
Depreciation 44 5 30
Profit before Tax 300 142 825
Extraordinary Income - -  
Tax 114 50 299
Profit after Tax/(Loss) 186 92 526
Net profit margin (%) 8.8% 8.9% 13.0%
No. of Shares (eoy) (m) 31.9 31.7 31.7
Diluted Earnings per share* 23.3 11.5 16.6
P/E (at current price) 17.5 12.2

Though the topline figures are more or less in line with market expectations, the operating margins have been disappointing. We were expecting a growth in operating margins on the back of four products launched by the company recently across different therapeutic segments. It appears that company's top brand Voveran (an anti-inflammatory) has witnessed degrowth in absolute terms in the current quarter.

At the current market price of Rs 202, the stock trades at 18 times 1QFY02 earnings. The future growth of the company depends on the success of the new products launched recently.

Equitymaster requests your view! Post a comment on "Novartis: Operating margins disappoints". Click here!


More Views on News

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

Why Super Investor Kenneth Andrade is Bullish on Agri Stocks...and So Are We(The 5 Minute Wrapup)

Jun 21, 2019

Andrade gives his take on agriculture, an industry from which we have already recommended two stocks.

This Little-Known Opportunity Promises Both Health and Wealth for Your Grandchildren(Profit Hunter)

Jun 20, 2019

The next big opportunity that has the potential to make you both rich and healthy.

My Upcoming Stock Recommendation, Backed by Aberdeen Standard Investments, Scores 9.1/10(The 5 Minute Wrapup)

Jun 19, 2019

This month's Smart Money Secrets recommendation is from global super investor - Aberdeen Standard Investments.


Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms


Jun 26, 2019 03:36 PM


  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks